DexCom and Abbott Diabetes Care entered a settlement and patent cross-license agreement, resolving all outstanding litigation between the companies.
The companies have been involved in global patent litigation, with both having accused the other of infringing certain patents, and each has filed counterclaims and actions to invalidate the other party's patents, DexCom said in a Securities and Exchange Commission filing Monday.
On Friday, the companies entered a settlement, under which both granted the other "a worldwide, royalty-free, non-exclusive, fully paid-up license to certain patents and patent applications relating to analyte sensing." This license extends to all the patents asserted in the litigation, DexCom said.
Also under the terms of the settlement, which does not obligate either company to pay royalties or any other form of financial compensation, both parties agreed to not sue until Dec. 20, 2034, and will not challenge the patents and patent applications licensed under the agreement, according to DexCom.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.